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1. Introduction
The general population is rapidly ageing due to socio-
economic and medicinal advances. It is estimated that in 
the near future, the population of children under 5 years 
will be outnumbered by elderly over 65 years old (Duncan 
and Flint, 2013). This global issue puts an overwhelming 
burden on healthcare systems in order to maintain a good 
quality of life (QoL) for elderly individuals (Duncan and 
Flint, 2013). Elderly (≥65 y) often suffer from more than 
one chronic condition, and approximately 87% of elderly 
individuals living at home receive at least one prescription 
drug (Barat et al., 2000).
It is well understood that ageing is associated with a change 
in the microbiota (Biagi et al., 2012). Ageing may cause a 
change in the Firmicutes to Bacteroidetes ratio (Mariat et al., 
2009). Also, there seems to be a decline in the heterogeneity 
of microbial species with, for example, bifidobacteria 
becoming less abundant (Biagi et al., 2012). Moreover, 
the microbiota of individuals in long stay residential care 
appeared to be less diverse when compared to community-
dwelling elderly (Claesson et al., 2012). A clear consensus 
on the changes of the microbiota upon ageing remains 
however to be established (Magrone and Jirillo, 2013), 
and also seems to be complicated by differences caused 
by geographical origin (Mueller et al., 2006). A disbalance 
in the microbiota is associated with a variety of illnesses 
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Abstract
Our aim was to determine whether a fermented milk drink containing probiotics could improve the bowel habits 
of frail elderly individuals living in a nursing home. A total of 135 participants were enrolled in this pilot study. The 
bowel habits (stool quality and bowel movements) were recorded by nursing staff during a baseline period of 3 weeks. 
After this period participants received daily a fermented milk drink containing minimally 6.5×109 colony forming 
units of Lactobacillus casei Shirota (LcS) for 6 weeks. During this period, bowel habits were recorded and compared 
to baseline period. Forty-four participants (74-99 years old) were compliant and used for analysis. Consumption 
of fermented milk containing LcS significantly increased the percentage of ideal stool types per week (P<0.01), 
lowered the percentage of constipation stool types per week (P<0.01) and significantly lowered the percentage of 
diarrhoea stool types per week (P=0.016) as compared to the baseline period. The study product had no significant 
effect on bowel movements. During the study, no changes in laxative usage or adverse events associated with the 
study product were reported. Our results suggest that a fermented milk containing LcS significantly improves the 
bowel habits of frail elderly residents in a nursing home. These promising results should be further substantiated 
by a confirmatory study.
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(Sekirov et al., 2010). For instance, there are indications 
that constipation may be associated with changes in the 
intestinal flora (Van Tongeren et al., 2005). Constipation 
is a disorder that is especially prevalent amongst the older 
population (Gandell et al., 2013). The prevalence in nursing 
homes seems to be even higher with respect to community-
dwelling elderly. An American study estimated that the 
prevalence of constipation may be as high as 74% in nursing 
homes (Rao and Go, 2010). In addition to the altered 
microbiota, certain disease states such as hypothyroidism, 
hypercalcemia, stroke and Parkinson disease as well as 
drugs commonly taken by elderly (e.g. antidiarrheal agents, 
calcium-channel blockers, oral iron supplements and opioid 
analgesics) are known causes for constipation (Gandell et 
al., 2013). Constipation is associated with a wide variety 
of complications, especially in the frail elderly population. 
It often leads to anorexia, nausea and pain associated with 
functional decline (Gandell et al., 2013). Furthermore, it 
can lead to a decreased QoL and increased costs for health 
care facilities to manage the problem.
Restoring the disbalanced microbiota to reduce disease 
risk by using probiotics might improve the overall health 
of elderly living in nursing homes. Probiotics are defined by 
the Food and Agricultural Organization and World Health 
Organization (FAO/WHO) as ‘live microorganisms that, 
when administered in adequate amounts, confer a health 
beneﬁt on the host’ (FAO/WHO, 2001); this consensus 
is recently reinforced by the International Scientific 
Association for Probiotics and Prebiotics (ISAPP; Hill et 
al., 2014). Several studies indeed demonstrate a beneficial 
potential of probiotics for constipation (Chmielewska 
and Szajewska, 2010; Koebnick et al., 2003). Hence, 
probiotic intervention amongst the residents may lead 
to an improvement of the QoL, due to a lowering of the 
constipation prevalence.
Antibiotic usage, which is relatively high in elderly, disturbs 
the gastrointestinal (GI) microbiota and may increase 
the incidence of a Clostridium difficile infection (Hell et 
al., 2013). This highly prevalent pathogen in the elderly, 
with a carriage rate of around 20% in home care residents 
(Karlström et al., 1998), can cause antibiotic-associated 
diarrhoea (AAD). Meta-analyses indicate that probiotics 
may be beneficial for the treatment of AAD (Hell et al., 
2013; Hempel et al., 2012; Videlock and Cremonini, 
2012). In addition, probiotics for non-AAD, which is also 
frequently encountered within the elderly population 
(Van Dessel et al., 2005), show promising results (Floch 
et al., 2011). Iatrogenic bowel irregularities, such as AAD 
and C. difficile-associated diarrhoea can lead to serious 
complications. Recent studies, however, demonstrate that 
administration of a commercially available probiotic leads 
to substantial healthcare cost-savings (Claassen, 2014).
Multiple studies focusing on management of diarrhoea or 
constipation using probiotics have appeared over the last 
years. However, to the best of our knowledge, no research is 
available that focuses on improving bowel habits (including 
both diarrhoea and constipation) of residents in nursing 
homes with a very high age. This pilot study therefore 
investigates the possibility to improve bowel habits using 
a fermented milk drink containing Lactobacillus casei 
Shirota (LcS) on frail elderly residents of a nursing home 
in the Netherlands.
2. Methodology
Design and outcome parameters
This food supplement pilot study was conducted in a 
nursing home in the Netherlands between March and May 
2013. The study was designed in two phases, a baseline 
period of 3 weeks (weeks 1-3) and an intervention period 
of 6 weeks (weeks 4-9; total of 63 days; Supplementary 
Figure S1). During the baseline period participants did not 
receive the study product. During the intervention period, 
participants received daily a fermented milk beverage.
The study product was a commercially available probiotic 
product, Yakult Original (YOR), containing a minimum of 
1.0×108 cfu/ml L. casei strain Shirota (YIT9029) per bottle. 
Participants orally received one bottle of 65 ml during 
breakfast per day (minimally 6.5×109 cfu/day). The study 
product was provided by Yakult Nederland BV (Amstelveen, 
the Netherlands).
During the complete course of 9 weeks, participants were 
accompanied to the bathroom by nursing staff to document 
the primary outcome of stool quality and bowel movements. 
Stool quality was determined according to the 7-point 
Bristol stool scale (developed by K.W. Heaton and S.J. Lewis, 
Bristol University). Bristol stool type 1 and 2 were associated 
with constipation, type 3 and 4 with ideal stool and type 5, 
6 and 7 with diarrhoea (Supplementary Figure S2). Bowel 
movements were calculated as the number of stools per 
time-unit and related to the Rome III criteria for functional 
constipation (Drossman et al., 2006). The criterion for 
functional constipation was ≤2 stools per week. In addition 
to bowel habits, other parameters, such as laxative usage 
and adverse events were monitored.
Study population and criteria
The study population consisted of ‘high maintenance’ 
frail elderly individuals, with a limited life-span (average 
~1.5 year), living in a nursing home. All participants were 
recruited from the same nursing home after informed 
consent was obtained from first degree relatives. Residents 
in the nursing home ageing ≥70 years were considered 
eligible for inclusion. Participants were excluded from 
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the study if (1) their life expectancy was ≤6 months; (2) 
required intensive medication; or (3) were severely ill (as 
determined by the in-house physician).
Subjects were accompanied to the bathroom by nursing 
staff. This also allowed for consistent and reliable data 
collection. In addition, during the baseline period of 3 
weeks, subjects were allowed to consume a maximum of 
two bottles of YOR. During the intervention period, subjects 
were allowed to miss a maximum of two bottles of YOR. 
During the complete course of the study, participants were 
not allowed to consume any other probiotic products. There 
were no major alterations in regular diet of the participants 
during the study as controlled by the institution.
Statistical analysis
The sample size was estimated based on data provided by 
Koebnick et al. (2003). Taking into account poor compliance 
and the sequential design of the study, a sample size of 135 
participants would provide sufficient power for this pilot 
study. All data were tested for normal distribution using 
a Shapiro-Wilk test in combination with Q-Q (Quantile-
Quantile) plots for additional verification. Normally 
distributed data were analysed using a paired t-test, 
whereas not normally distributed data were analysed using 
a Wilcoxon-signed rank test (a non-parametric test). Data 
analysis was performed using R Studio (version 0.98.501) 
statistical software, and IBM SPSS statistics v.20 (IBM, 
Armonk, NY, USA). A P-value <0.05 was considered 
significant.
3. Results
In total 135 subjects gave consent and were recruited to 
participate in the study. Table 1 describes the baseline 
characteristics of the study population. Due to serious non-
compliance (subjects went to the bathroom independently), 
only 44 subjects with all data on bowel habits available were 
considered eligible for analysis. The age range of the per-
protocol (PP) population was 74-99 years old (mean 83.8 y).
There was no difference in laxative usage; the average 
number of laxatives used per patient per week during 
intervention was not significantly different from the 
baseline period (P=0.091). Seven subjects (15.9%) did 
not receive laxatives during the entire study duration. All 
laxatives were empirically supplemented, with Movicolon 
as the most frequent prescribed laxative. Other laxatives 
were lactulose, plum compote, bisacodyl, Norgalax and 
magnesium-oxide (MgO).
The total number of stools per week per participant during 
the baseline period was 5.2±1.5 compared to 5.4±1.7 stools 
per week during the intervention period (P=0.236; Figure 
1A). When comparing the percentage of ideal stools 
(type 3 and 4) during the baseline- and intervention period, 
36 (~82%) participants experienced an improvement in 
stool quality, whereas, for 8 (~18%) participants the stool 
quality worsened. The percentage of ideal stools per week 
during the intervention, as compared to baseline period 
was significantly higher (61.4±28.6% vs 47.8±29.4%; 
P<0.01; Figure 1B). When comparing the percentage of 
constipation-associated stool types (type 1 and 2) during the 
baseline- and intervention period, 21 (~48%) participants 
experienced an improvement, 16 (~36%) participants 
experienced no difference and for 7 (~16%) participants 
the stool quality worsened. Overall, there was a significantly 
lower percentage of constipation stool types per week 
during intervention, compared to baseline (5.4±13.8% vs 
13.2±23.5%; P< 0.01; Figure 1C). When comparing the 
percentage of diarrhoea-associated stool types (type 5, 
6 and 7) during the baseline- and intervention period, 
26 (~59%) participants experienced an improvement, 1 
(~2%) participant experienced no difference and for 17 
(~39%) participants the stool quality worsened. Overall, 
there was a significant lower percentage of diarrhoea stool 
types per week during intervention, compared to baseline 
(33.2±27.7% vs 39.0±31.6%; P<0.05; Figure 1D).
Consumption of the probiotic product did not lower 
the number of patients obeying Rome III criterion (≤2 
defecations per week) during the intervention period 
compared to the baseline (P>0.05). The study product 
was well tolerated in all the participants. There occurred 
no adverse events (AEs) related to the study product during 
the trial.
Table 1. Demographics and characteristics of the participants.1
Enrolled subjects, n 135
Drop-out rate, n (%) 91 (67.4)
Mortality, P1/P2 (%) 4.4 / 2.3
Per protocol subjects, n 44
Male/female, n/n 11 / 33
Age, mean ± SD, y 83.8±5.9
Laxative usage (%)
Lactulose 9.6
MgO 7.0
Movicolon 49.0
Norgalax 4.2
Plum compote 29.0
Others 1.0
1 Abbreviations used: P1 = baseline period; P2 = intervention period; SD 
= standard deviation; MgO = magnesium-oxide; Others = other laxatives 
are enema and bisacodyl.
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Figure 1. (A) Bowel movements, (B) ideal stool, (C) constipation and (D) diarrhoea. The displays show the improvements for each 
patient in percent points regarding the incidence of specified stool types per week (ideal/constipation/diarrhoea) between the 
intervention and baseline period respectively. Each figure is accompanied by its respective Q-Q-plot as a check for normality. C 
is not normally distributed.
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4. Discussion
The data of this pilot study indicate that LcS fermented 
milk can significantly improve bowel habits of frail elderly 
residents in a nursing home. The use of a probiotic drink 
containing LcS is already associated with boosting the 
immunity of elderly volunteers, for instance, by increasing 
the natural killer cell activity and displaying a more anti-
inflammatory cytokine profile (Dong et al., 2013). This 
suggests that probiotics can induce in addition to a local 
gastrointestinal effect, a far more widespread beneficial 
systemic effect.
The percentage of diarrhoea-associated stools (type 5, 6 
and 7) per week was significantly lower during the probiotic 
intervention as compared to the baseline period. This might 
suggest that administration of a probiotic fermented milk 
beverage can reduce the incidence of diarrhoea in elderly 
residents in a nursing home. Indeed in children ageing 1-5 
y, administration of LcS had a protective effect of 14% (95% 
CI: 4-23, P<0.01) for diarrhoea (Sur et al., 2011). Whether 
the stool types 5, 6 and 7 in the elderly were caused by 
AAD remains to be determined; stool types were not 
stratified for antibiotics usage. Wright et al. (in press), 
were not able to demonstrate an effect of a LcS-containing 
beverage on AAD in geriatric patients. However, this study 
was underpowered to detect a significant effect and the 
administration period was relatively short (Wright et al., in 
press). LcS supplementation did show promising results in 
lowering the incidence of AAD (17.1 vs 54.9%, P<0.001) in 
patients with spinal cord injuries compared to the control 
group (Wong et al., 2014).
The percentage of constipation-associated stools (type 
1 and 2) per week was significantly lower during the 
probiotic intervention compared to the baseline period. 
However, there was no significant difference in percentage 
of participants with ≤2 defecations per week. Whether 
supplementation with LcS improves stool consistency and 
defecation frequency in constipated participants remains 
questionably, as literature does not provide convincing 
evidence (Koebnick et al., 2003; Mazlyn et al., 2013; Sakai 
et al., 2011). If this is due to a relatively short intervention 
period remains to be determined. It is not unlikely that 
improvements in defecation frequency will be observed 
only after long-term administration. The reduction of both 
diarrhoea and constipation associated stool types resulted in 
a significantly higher percentage of ideal stool type (type 3 
and 4) per week during the probiotic intervention compared 
to the baseline period.
Although the total number of bowel movements did not 
differ significantly compared to the baseline, other studies 
did show a moderate effect. In a randomised placebo-
controlled trial, administration of LcS in healthy individuals 
with soft stools significantly improved the stool quality and 
decreased the defecation frequency (Matsumoto et al., 
2010). In constipated female students, consumption of a 
synbiotic fermented milk beverage containing LcS resulted 
in a significant increase in bowel movements compared 
to the placebo group (Shioiri et al., 2006). Whereas these 
studies solely evaluated relatively healthy individuals with 
soft stool types and individuals with constipation, this 
current study demonstrated an improvement of all stool 
types (both diarrhoea and constipation) in relatively frail 
elderly individuals (as mentioned in the results).
The observed results in bowel habits were not related to a 
difference in laxative usage between the intervention- and 
baseline-period. The laxative intake was not significantly 
different during the intervention period compared to the 
baseline, demonstrating that the observed improvement in 
bowel habits can indeed be attributed to the introduction of 
the probiotic product and cannot be ascribed to changes in 
laxative usage. However, a further stratification of the data 
on laxative usage is, in this study, not possible due to limited 
number of patients that could be included for the statistical 
analysis. Preferably, a reduction in laxative usage is observed 
during the intervention period. However, there were no 
predetermined criteria for prescribing laxatives. Therefore 
it is possible that nursing staff were inclined to administer 
laxatives (e.g. plum compote), even if not necessary.
During this pilot study, no AEs were reported. This is in 
line with a previous study of van Puyenbroeck et al. (2012) 
were 737 individuals aged ≥65 y in nursing homes were 
randomly assigned to receive a LcS (n=375; 1.3×1010 cfu 
LcS/day) or a placebo (n=362) for 21 days. During this study 
there were no AEs reported associated with consumption of 
L. casei Shirota, further advocating the safety of this strain 
in relative fragile individuals (Van Puyenbroek et al., 2012). 
In addition, no AEs were reported in very old individuals 
(mean age of 83 y) consuming a high dosage of 4.0×1010 
cfu LcS/day (Nagata et al., 2011). Currently, there are no 
indications that probiotics are unsafe in a controlled setting, 
even in preterm infants and severely immune comprised 
adults (Van den Nieuwboer et al., 2014, 2015). Indeed, the 
FAO designated a GRAS (generally recognised as safe) 
status to LcS (GRN000429).
In short, these data indicate that a LcS fermented milk 
beverage significantly improves stool quality of frail elderly 
residents of a nursing home by a reduction of diarrhoea 
and constipation stool types and an increase in ideal stool 
types. These promising results should be confirmed by 
a randomised, controlled, parallel study. Whereas other 
strains (e.g. LGG) already have a well-established evidence-
base for diarrhoea (Floch et al., 2011), data to support the 
use of LcS to improve bowel habits is still in development. If 
these data can be confirmed, there is a huge opportunity to 
significantly improve the QoL of elderly in nursing homes 
and reduce healthcare costs and workload.
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Supplementary material
Supplementary material can be found online at http://
dx.doi.org/10.3920/BM2014.0113.
Figure S1. Sequential trial lay-out.
Figure S2. Bristol stool scale.
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